The growth, proliferation, and metastasis of HR+/HER2-breast cancer cells are intricately regulated by the estrogen receptor signaling pathway [3], rendering endocrine therapy (ET) the cornerstone clinical intervention for hormone level regulation. This evidence concerns the gene ERBB2 and breast carcinoma.